Updated for 2026
AGPCNP chronic disease management: modified targets for older adults with multimorbidity
Chronic disease management in the AGPCNP certification reflects the complexity of older adults with multimorbidity — where guideline recommendations for single diseases must be modified for patient safety, functional status, and goals of care. The AGPCNP exam tests how to apply and adapt evidence-based guidelines to the geriatric context.
Educational purpose: This content is for exam preparation and professional development only. It is not intended for clinical decision-making. Always follow current guidelines, institutional policies, and scope of practice.
Hypertension management in older adults — when to modify targets
SPRINT trial and older adults: SPRINT demonstrated mortality benefit from intensive BP target (<120 mmHg systolic) in adults ≥75 with high cardiovascular risk — excluding patients with dementia, diabetes, or prior stroke. Benefits were maintained in older adults, but the trial used automated office blood pressure (AOBP) which gives readings ~5 mmHg lower than standard office measurement.
When to use less stringent targets in older adults:
- Frailty with orthostatic hypotension: Aggressive lowering risks falls and syncope. Check standing BP at each visit in older adults on antihypertensives.
- Dementia: Falls from antihypertensive-induced hypotension may cause greater harm than mild BP elevation
- Life expectancy <5 years: Cardiovascular risk reduction becomes less meaningful; focus on symptom management
- Multiple comorbidities with polypharmacy burden: Benefits of adding additional antihypertensives must be weighed against medication burden
Orthostatic hypotension: Systolic drop ≥20 mmHg or diastolic drop ≥10 mmHg within 3 minutes of standing. Common in older adults — assess at each visit. Causes: dehydration, antihypertensives, alpha-blockers (especially doxazosin for BPH), diuretics, dopaminergic medications, Parkinson disease. Management: adequate hydration, compression stockings, rise slowly, medication review.
Diabetes management in older adults — individualised targets
ADA 2024 individualised A1C targets in older adults:
- Healthy older adults (good functional status, few comorbidities, intact cognition): A1C <7–7.5%
- Complex older adults (multiple chronic illnesses, ADL impairment, cognitive impairment): A1C <8%
- Very complex/poor health (frailty, end-stage disease, limited life expectancy): A1C <8–9% (avoid hypoglycaemia; glucose comfort >clinical tight control)
Hypoglycaemia in older adults: Heightened risk and greater harm — can precipitate falls, fractures, cardiac events, cognitive decline. Avoid sulfonylureas (glipizide slightly preferred over glyburide in elderly — shorter acting, fewer active metabolites). Avoid insulin regimens with high hypoglycaemia risk without appropriate patient/caregiver training.
Metformin in older adults with CKD: Hold or reduce dose at eGFR <45; contraindicated at eGFR <30. In eGFR 30–45: reduce to 1000 mg/day max. Annual or biannual renal function monitoring for all elderly patients on metformin.
Frequently asked questions
- How should the AGPCNP approach a patient with multiple chronic conditions and conflicting guideline recommendations?
- Multimorbidity requires a patient-centred, goals-of-care approach rather than applying individual disease guidelines in isolation. The American Geriatrics Society (AGS) framework for multimorbidity recommends: (1) Elicit patient priorities — what matters most to this patient (living longer, maintaining function, staying independent, managing symptoms)? (2) Interpret the evidence considering the patient's entire situation — were clinical trials that generated the guidelines done in patients like this (older, multiple comorbidities, frailty)? Most landmark trials excluded older adults with multimorbidity. (3) Consider interactions — treatments for one condition may worsen another (NSAIDs for arthritis worsening heart failure or CKD). (4) Reduce treatment burden — polypharmacy, frequent monitoring, and complex regimens reduce quality of life and adherence. (5) Regularly reassess whether the treatment plan still aligns with goals as health status changes.
Clinically reviewed by NurseNest Clinical Review Team · Last updated 2026-06-10 · For educational purposes only · Review policy